Abstract:Background and Aims: The aims of this study were to establish a maximum standardized uptake value (SUVmax) cutoff to discriminate clinically significant prostate cancer (csPCa) from benign prostate disease (BPD) by Ga-68-labeled prostate-specific membrane antigen (Ga-68-PSMA-11) positron emission tomography/computed tomography (PET/CT) in patients with suspected prostate cancer (PCa), and to perform a prospective real-world validation of this cutoff value.Methods: The study included a training cohort to identify an SUVmax cutoff value and a prospective real-world cohort to validate it. A retrospective analysis assessed 135 patients with suspected PCa in a large tertiary care hospital in China who underwent Ga-68-PSMA-11 PET/CT. All patients were suspected of having PCa based on symptoms, digital rectal examination (DRE), total prostate-specific antigen (tPSA) level, and multiparameter magnetic resonance imaging (mpMRI). The Ga-68-PSMA PET/CT results were evaluated using histopathological results from transrectal ultrasound-guided 12-core biopsy with necessary targeted biopsy as references. Patients with Gleason scores (GS) >= 7 from the biopsy results were diagnosed with csPCa, and patients with negative biopsy and follow-up results were diagnosed with BPD. Receiver operating characteristic (ROC) curve analysis was used to identify the optimal SUVmax cutoff value. The cutoff value was prospectively validated in 58 patients with suspected PCa. The diagnostic benefits of the cutoff value for clinical decision making were also evaluated.Results: According to ROC curve analysis, the most appropriate SUVmax cutoff value for discriminating csPCa from BPD was 5.30 (sensitivity, 85.85%; specificity, 86.21%; area under the curve [AUC], 0.893). The cutoff achieved a sensitivity of 83.33%, a specificity of 81.25%, a positive predictive value (PPV) of 92.11%, a negative predictive value (NPV) of 65.00%, and an accuracy of 82.76% in the prospective validation cohort. Metastases were used as an indicator to reduce false negative results in patients with SUVmax <= 5.30. In patients without metastases, an SUVmax value of 5.30 was also the best cutoff to diagnose localized csPCa (sensitivity, 80.43%; specificity, 86.21%; AUC, 0.852). The cutoff discriminated localized csPCa from BPD with a sensitivity of 76.19%, a specificity of 81.25%, a PPV of 84.21%, an NPV of 72.22%, and an accuracy of 78.38% in the prospective validation cohort. The cutoff, combined with metastases, achieved an accuracy of 89.12% in all patients, increasing accuracy by 8.29% and reducing equivocal results compared with manual reading. There was a strong correlation between SUVmax and PSMA expression (r(s) = 0.831, P < 0.001) and a moderate correlation between SUVmax and GS (r(s) = 0.509, P < 0.001). The PSMA expression and SUVmax values of patients with csPCa were significantly higher than those of patients with BPD (P < 0.001).Conclusion: We established and prospectively validated the best SUVmax cutoff value (5.30) for discriminating csPCa from BPD with high accuracy in patients with suspected PCa. 5.30 is an effective cutoff to discriminate csPCa patients with or without metastases. The cutoff may provide a potential tool for the precise identification of csPCa by Ga-68-PSMA PET/CT, ensuring high accuracy and reducing equivocal results.

Evaluating the Value of 18F-PSMA-1007 PET/CT in the Detection and Identification of Prostate Cancer Using Histopathology As the Standard

The value of 18F-PSMA-1007 PET/CT in identifying non-metastatic high-risk prostate cancer

18F-PSMA-1007 PET/CT-derived Semi-Quantitative Parameters for Risk Stratification of Newly Diagnosed Prostate Cancer

Intra-Individual Comparison Of 18f-Psma-1007 And 18f-Fdg Pet/Ct In The Evaluation Of Patients With Prostate Cancer

68Ga-PSMA PET/CT and Prostate Cancer Diagnosis: Which SUVmax Value?

19-1648 PSMA UPTAKE ON 68GA-PSMA-11-PET/CT POSITIVELY CORRECTS WITH PROSTATE CANCER AGGRESSIVENESS

Evaluation of 18F-PSMA-1007 PET/CT in Prostate Cancer Patients with Biochemical Recurrence after Radical Prostatectomy

18F-PSMA-1007 PET/CT Performance on Risk Stratification Discrimination and Distant Metastases Prediction in Newly Diagnosed Prostate Cancer

Selection and Validation of an SUV Max Cutoff Value to Discriminate Prostate Cancer from Benign Prostate Hypertrophy by 68Ga-Psma PET/CT: A Real-World Study

PSMA Uptake on [68Ga]-Psma-11-pet/ct Positively Correlates with Prostate Cancer Aggressiveness.

F-18-PSMA-1007 PET/CT Performance on Risk Stratification Discrimination and Distant Metastases Prediction in Newly Diagnosed Prostate Cancer

Establishment And Prospective Validation Of An Suvmax Cutoff Value To Discriminate Clinically Significant Prostate Cancer From Benign Prostate Diseases In Patients With Suspected Prostate Cancer By Ga-68-Psma Pet/Ct: A Real-World Study

18F-PSMA-1007 PET/CT in Primary Prostate Cancer: Using Tpsa to Detect Distant Metastasis and Incorporating SUVmax to Characterize Primary Prostate Cancer and Distant Metastasis

A Single-Center, Multi-Factor, Retrospective Study to Improve the Diagnostic Accuracy of Primary Prostate Cancer Using [68Ga]ga-Psma-11 Total-Body PET/CT Imaging.

18F-Dcfpyl PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer

A Prostate-Specific Membrane Antigen PET-Based Approach for Improved Diagnosis of Prostate Cancer in Gleason Grade Group 1: A Multicenter Retrospective Study

Improving diagnostic efficacy of primary prostate cancer with combined 99mTc-PSMA SPECT/CT and multiparametric-MRI and quantitative parameters

The Prognostic Value of 18F-PSMA-1007 PET/CT in Predicting Pathological Upgrading of Newly Diagnosed Prostate Cancer from Systematic Biopsy to Radical Prostatectomy

BPH-related false positive of 68 Ga-PSMA PET/CT in the diagnosis of prostate cancer: The Achilles heel of biopsy-free radical prostatectomy?

(1) PSMA PET/CT and standard plus PET/CT-Ultrasound fusion targeted prostate biopsy can diagnose clinically significant prostate cancer in men with previous negative biopsies (2) PSMA PET/CT-Ultrasound prostate biopsy

Predictive value of volumetric parameters based on 18F-PSMA-1007 PET/CT for prostate cancer metastasis